You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.

This message is from a valued third-party sponsor. It should not be considered a recommendation or endorsement by Benzinga.

Revolutionizing Colorectal Cancer Prevention

Mainz Biomed (NASDAQ: MYNZ) has enrolled its first patient in its groundbreaking eAArly DETECT 2 study, marking a potential paradigm shift in colorectal cancer management.

The innovative test combines proprietary mRNA biomarkers with AI algorithms to detect not just early-stage cancer but also precancerous lesions — potentially preventing the disease entirely.

With 2,000+ average-risk patients enrolled and results expected by late 2025, this technology could transform cancer care from detection to prevention.

Check out this opportunity to be part of the colorectal cancer revolution – visit mainzbiomed.com/investors today to learn how you can support or invest in this life-saving innovation.

This is a paid ad. Please see 17b disclosure here for more information.